|
|
Volumn 113, Issue 2, 2010, Pages 190-
|
|
Monoclonal antibodies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
IODINE 125;
METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;
TEMOZOLOMIDE;
VASCULOTROPIN;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG TARGETING;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
GLIOBLASTOMA;
HUMAN;
IMMUNE RESPONSE;
KARNOFSKY PERFORMANCE STATUS;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RADIOIMMUNOTHERAPY;
TREATMENT OUTCOME;
TUMOR CELL DESTRUCTION;
ANTIBODIES, MONOCLONAL;
BRAIN NEOPLASMS;
GLIOBLASTOMA;
HUMANS;
RADIOIMMUNOTHERAPY;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 77955609179
PISSN: 00223085
EISSN: 19330693
Source Type: Journal
DOI: 10.3171/2010.1.JNS091894 Document Type: Editorial |
|
Times cited : (1)
|
|
References (1)
|
